11th Edition Clinical Trials in Canada

$499.00

SKU: PHP10622 Category:

Description

Report Code: PHP10622. October, 2010. Toronto, ON

ARTICLE I

Canadian Bioitechnology Industry Overview

Graeme Fraser
Director, Health Policy
BIOTECanada

ARTICLE II

New Horizons in Clinical Trials

Pierre Gervais B.Pharm. M.Sc.
Q&T Research Sherbrooke – President, Executive Director

ARTICLE III

The Future of Clinical Trials in Canada: A Perspective from Health Canada

Norman Viner, M.D.
Chief, Clinical Trial Division
Biologics and Genetic Therapies Directorate
Health Canada

ARTICLE IV

Making Personalized Medicine a Reality: New Imaging Technologies from Bench to Bedside

Justin Lee, MD, MSc, FRCPC
Odette Cancer Centre
Sunnybrook Health Sciences

ARTICLE V

Personalized Medicine and Clinical Trials

Philip Plotnick
Managing Director
Mount Sinai Services

Ronald J. Heslegrave, PhD
Chair, Research Ethics Board Mount Sinai Hospital and Senior Scientist
University Health Network

P. Bradley Limpert
Partner, Patent and Trade Mark Agent
Cameron Mackendrick LLP

ARTICLE VI

Personalized Medicine and Clinical Trials: Ethical Considerations

Ronald J. Heslegrave, PhD
Chair, Research Ethics Board Mount Sinai Hospital and Senior Scientist
University Health Network

ARTICLE VII

Personalized Medicine: Key Legal Issues

P. Bradley Limpert
Partner, Patent and Trade Mark Agent
Cameron Mackendrick LLP

ARTICLE VIII

Vaccine Development

Monica Bologa, MD
Director, Clinical Development
sanofi pasteur

ARTICLE IX

From Research to Approval to Access – Regulatory Developments and Innovations at Home and Abroad

Milton Egas
Manager, Clinical Quality Assurance
AstraZeneca Canada Inc.

ARTICLE X

We Have Health Canada Approval – Now What?

Kim McDonald-Taylor
Director, Clinical Services – Wyatt Health Management
President, Clinical Research Association of Canada

ARTICLE XI

Recruitment – Enrollment – Retention: Maximizing Your Return on Investment (ROI)

Darren Cowan-Bittner, Head of Monitoring
Clinical Research, Western Canada
Pfizer Canada Inc.

ARTICLE XII

Collaboration, Networks and Partnerships: The Southlake Experience

Patrick Clifford, BA, BSW, BEd, MSW, RSW
Director of Research
Southlake Regional Health Centre

ARTICLE XIII

Collaboration, Networks and Partnerships – Can They Really Resolve Your Worst Clinical Research Headaches?

Dr. Carter Thorne, MD
Secretary-Treasurer
Canadian Rheumatology Research Consortium

Ronald Fehst
Institutional Review Board Services

ARTICLE XIV

Managing, Minimizing and Allocating Risk in Global Clinical Trials

Andrew Loh
Partner
Borden Ladner Gervais LLP

ARTICLE XV

Web 2.0 and Patient Participation, Protection and Emancipation in Research Trials

Pierre Gervais, B.Pharm., M.Sc.
President, Research Director
Q&T Research, Sherbrooke

Karine Côte, RN, Bsc. Adm.
Associate Director, Operation and Recruitment
Q&T Research, Sherbrooke

ARTICLE XVI

Meeting the Challenges of Paediatric Clinical Trials

Richard Sugarman
Chair, Research Ethics Board
The Hospital for Sick Children

ARTICLE XVII

Oversight Reform – Latest Thinking on Research Ethics Boards and Approvals

Jack Corman
Founder and President
Institutional Review Board Services

ARTICLE XVIII

Oversight Reform – Latest Thinking and Developments for REBs

Richard Sugarman
Chair
SickKids REB

ARTICLE XIX

Oversight Reform – Latest Thinking and Developments on Research Ethics Boards and Approvals

Susan V. Zimmerman
Executive Director
Interagency Advisory Panel on Research Ethics

ARTICLE XX

Strong Financial Management in Clinical Trials – The Latest Tools and Strategies

Sandra Gazel
Associate Director, Clinical Research
Abbott Laboratories Limited

Lisa Johnston, RN, BScN, CCRP
Manager, Department of Clinical Research Practice
University Health Network

ARTICLE XXI

When Things Go Wrong: Who to Tell and What to Do About Data Breaches?

Patricia Kosseim
General Counsel
Office of the Privacy Commissioner of Canada